Abstract: So far, we still lack a clear molecular mechanism to explain the protein-ligand interaction on the basis of electronic structure of a protein. By combining the calculation of the full electronic structure of a protein along with its hydrophobic pocket and the perturbation theory, we found out two rules on the protein-ligand interaction. One rule is that the interaction only occurs between the lowest unoccupied molecular orbitals (LUMOs) of a protein and the highest occupied molecular orbital (HOMO) of its ligand, not between the HOMOs of a protein and the LUMO of its ligand. The other rule is that only those residues or atoms located in both the LUMOs of a protein and a surface pocket of a protein are active residues or active atoms of the protein and the corresponding pocket is the ligand binding site. These two rules are derived from the structure of energy levels of a protein and could be one of important criterions of the drug design. They were validated on complex CypA/CsA and FKBP12/FK506. Furthermore, a tripeptide Ala-Gly-Pro (AGP) was predicted to bind to CypA as an application of our two rules. And the biological assays results show that AGP has the same order of binding affinity and inhibition of PPIase activity as CsA.
INTRODUCTION
Understanding ruling principles of interactions between a target protein and a ligand is of paramount importance in drug discovery efforts. So far, in finding a real ligand for a given target protein, we are limited to experimental screening from a large number of small molecules, or through free energy calculations of assessing a ligand. However, we still lack a clear molecular mechanism to explain the protein-ligand interaction on the basis of electronic structure of a protein and guide novel molecules designing. Here we report two rules on the protein-ligand interaction, derived from full electronic structure calculation of a protein. These two rules may serve as a new means of drug design and exploring enzyme reaction.
The full electronic structure calculation of a protein has been a challenge, as the system of a protein is huge and complicated. We use the overlapping-dimer approximation (ODA) [1] [2] [3] and the extended negative factor counting (ENFC) [4] methods to calculate the electronic structure of a protein. These two methods were first developed by J. Ladik and Y. J. Ye et al. [1, 4] We further clarified and revised some parts to facilitate calculations of proteins with over 600 residues.
The ODA uses the divide and conquer algorithm, which works by recursively breaking down a complex problem into many subproblems of the same (or related) type of the same scale. These subproblems are independent of each other, and their characters are the same as the original problem. We can use the solutions of these small subproblems to get the solution of the original problem. First of all, the whole chain of a protein is divided into many dimers, each containing two amino acid residues, and then we can perform any quantum calculation methods for these dimers; finally, construct the full Hamiltonian matrix using the solution of each dimer and use the ENFC math method to get the energy eigenvalues and the orbital coefficients of the wave function of a protein. It should be noted that the surrounding environment of each dimer and the water environment of a protein are applied in the process.
We take the protein-ligand complex Cyclophilin A (CypA) and its ligand Cyclosporin A (CsA), and FKBP12 of the protein family FKBPs and its immunosuppressant FK506 as examples to validate our two rules, and the results obtained are in good agreement with experiments. Furthermore, as an application of our two rules, a tripeptide AGP was predicted to bind to CypA and the biological assays results show that AGP has the same binding affinity and inhibition of PPIase activity as CsA.
The system of a protein molecule is so large that the energy levels are extremely compact. Therefore, for a protein system, we need to extend the definition of the frontier orbitals to be a series of HOMOs and LUMOs, not just limited to be a single HOMO or LUMO. Ordinarily, the first 10 to 20 occupied molecular orbitals and the unoccupied ones are considered to be HOMOs and LUMOs, respectively. For example, protein CypA has a total of 4807 occupied molecular orbitals. We considered the first 10 highest occupied molecular orbitals to be its HOMOs and the first 10 lowest unoccupied molecular orbitals as its LUMOs. The 10 HOMOs comprise only 0.2% among total 4807 occupied molecular orbitals.
MATERIALS AND METHODS

Full Electronic Structure Calculation
We used ODA and a math method ENFC to calculate the electronic structure of protein CypA (165 residues) and FKBP12 (107 residues). After molecular dynamic (MD) simulation, we obtained the coordinates of the proteins and ligands at temperature of interest. We needed to transform the format of these pdb files into ODA format. Then, we followed the four steps of ODA mentioned above to calculate their eigenvalues, orbital coefficients of wave functions and density of state.
We used program ArgusLab [5] to calculate the HOMO and the LUMO of ligand CsA and FK506.
Designing of Peptide Inhibitor AGP
How to create this novel ligand AGP? The procedure is like Hidden Markov Chain's (HMM) as follows:
(1). Selecting an Initial Residue Pro
MJ matrix (the effective inter-residue contact energy evaluated by Miyazawa and Jernigan [6, 7] ) is introduced to refine an active residue, with which the active residue Phe113 of CypA should has the lowest contact energy. Phe113 is taken as a target residue, and has the lowest contact energy with Pro (-4.25 RT) from the MJ matrix. In other words, Phe is the target of the highest probability to be bound by Pro. Therefore, residue Pro is the best option as the active residue of ligand.
Besides, the binding pocket is mainly composed of hydrophobic or non-polar residues. Therefore, the active part of the ligand fitting into the binding pocket should also be hydrophobic or non-polar. Pro happens to be a hydrophobic and non-polar residue.
(2). Taking Peptides as a Markov Chain to Calculate the HOMO
Suppose a peptides is composed of n residues, S = S 1 ,S 2 ,S 3 ,...,S n . If we take it as a Markov Chain, then its probability is P(S) = P(S 1 )P(S 2 | S 1 )P(S 3 | S 2 )LP(S n | S n!1 )
According to Bayes formula, we have
Therefore, we can calculate the HOMO one pair residues by one pair residues.
First, we calculate HOMO of dipeptide X-Pro, where X represents one of the 20 residues. And, the HOMO vs. MJ contact energy is shown in Fig. (1) . We can see that Gly-Pro, Ala-Pro, Val-Pro, Ile-Pro and Thr-Pro are of high HOMO energies, and the highest one is Gly-Pro. This can perfectly explain the suggestion proposed by Vajdos et al. [8] that CypA can function as a sequence-specific binding protein, with a strong preference for the sequence X-Gly-trans-Pro, which challenges the long-held assumption that CypA functions primarily as a non-specific proline isomerase.
Our two rules tell us that the potential ligand candidate should satisfy the following two conditions. 1) The higher the HOMO energy of a ligand candidate is the better, as the LUMO energy of the given target protein CypA is fixed.
2) The active atoms of a ligand candidate should be closed to the active atoms of CypA, such as those of Phe113 and Phe60. Therefore, we select Gly-Pro from dipeptides X-Pro, and then fix Gly to calculate the HOMO of dipeptide X-Gly (Fig. 1) . Dipeptides Ala-Gly, Val-Gly, Tyr-Gly, Phe-Gly and Arg-Gly are of high HOMO energy, and the highest one is Ala-Gly. Therefore, the best tripeptide is Ala-Gly-Pro (AGP) as a combination of X-Gly and X-Pro dipeptides. It can explain the previous findings that CypA recognition of hexapeptides involves contacts with peptide residues Ala, Gly and Pro, and is independent of the context of longer sequences [8] .
Docking
The program Autodock [9] was employed to dock the AGP initial conformation into the binding site of CypA. A grid box was centered in the ligand binding site and sized of 60x56x60 points to embrace all the residues making up the binding pocket using the default grid spacing 0.375. The active residue Phe113 of CypA was set as flexible one and the AGP was placed above the ligand binding site. We used the Larmarckian genetic algorithm (LGA) for docking with the number of energy evaluations of 2,500,000 and the maximum number of generation of 27000. And 100 LGA runs were performed.
Molecular Dynamic (MD) Simulation
Complex CypA/CsA and FKBP12/FK506 were performed MD simulation to obtain the ground state and the state of 300 K, respectively. Their starting coordinates were taken from the protein database bank [10] (PDB) with entry 1CWK and 1FKJ, respectively. The parallel MD program we used is NAMD [11] and all the molecules were solvated before the MD simulation.
However, for a ligand or other small molecules, there is often no topology and parameter information in the standard CHARMM's library. In that case, the web site HIC-UP [12] can help us to find the topology and parameter files for these small molecules. These files are X-PLOR version [13] , not CHARMM version. The ligand FK506 was treated in this way.
For ligand CsA, a cyclic undecapeptide with the following primary structure: MeBmt1-Abu2-Sar3-MeLeu4-Val5-MeLeu6-Ala7-D-Ala8-MeLeu9-MeLeu10-MeVal11. Residues 1, 3, 4, 6, 9, 10 and 11 are N-methylated on the amide nitrogen. Here, we created its topology and parameter information based on existing topology information from other molecules.
The basic idea to create the topology file of CsA is as follows:
(1) For residues MeBmt1 and Abu2, of which both not belong to the 20 kinds of standard residues of protein, we need to write out their topology files. Details of creating these two topology files can be found at the book 6 from page 125 to 139.
(2) We used program PSFGEN [11] to build the protein data bank (PDB) file and protein structure file (PSF) of CsA by using a patch LINK to link MeBmt1 and MeVal11 since it's a cyclic molecule and a patch METH to methylate the amide nitrogen of resides 1, 3, 4, 6, 9, 10 and 11.
After we get the topology file of CsA, we can use the program PSFGEN to build its new PDB and PSF files.
PSFGEN, a CHARMM version, can generate a revised PDB and PSF files with hydrogen atoms added, as well as the water environment For protein CypA, consisting of 165 residues and 2053 atoms, we also used the PSFGEN to get its new PDB and PSF files.
Finally, we set up the configuration file to run the MD simulation. The parameters for CHARMM force field was selected as follows: exclude = scaled 4, 1-4 scaling = 1.0, switching = on, switchdist = 8 Å, cutoff = 12 Å, pairlestdist = 13.5. We minimized the CypA and CsA for 80ps, separately.
For ligand FK506, with chemical formula C44H69NO12, we get its topology and parameter files from HIC-UP server and run program XPLOR64 [13] to get its new PDB and PSF file. The XPLOR64, a XPLOR version, can generate a revised PDB and PSF files using topology file obtained from CNS [13] .
For protein FKBP12, we also used XPLOR to generate its new PDB and PSF files.
We use the same MD parameters as CypA/CsA for FKPB12 and FK506 separately. They were firstly relaxed to near 20 K by running 20 ps. And then it was heated continuously from 20K to 290K with the temperature step 30 K, running 30 ps for each step. And we performed a smaller temperature step 5 K from 295 K to 300 K with 30 ps each step. Finally, run 50 ps at 300 K. The total time scale is 520 ps for the whole process using 16 CPUs. The same energy minimization procedure was applied on the complex system of CypA/AGP suggested by docking.
Proteins and Compounds
The full-length coding sequence of CypA was inserted in frame into plasmid pET28a (Clontech) to generate recombinant human CypA protein. HIS-CypA protein was expressed and purified ( Fig. 2) . CsA, the substrate Nsuccinyl-Ala-Ala-Pro-Phe-p-nitroanlilide (Suc-AAPF-pNA), α-chymotrypsin, and 2,2,2-trifluorethanal (TFE) were purchased from Sigma (St. Louis, MO). The peptides were purchased from Shanghai science peptide biological technology co., LTD.
Surface Plasmon Resonance (SPR) Analysis
Recombinant human CypA protein (10 µM) was immobilized on a carboxylmethylated dextran surface (CM5 chip from Biacore, Inc., Piscataway, NJ) in a buffer containing 10 mM sodium acetate (pH 4.0) using standard amine coupling chemistry procedure following the manufacturer's instructions. Flow cell 1 was used as the control surface and flow cell 2 contained 4000 resonance units (RU) of CypA protein (1 RU corresponds to 1 pg of protein per mm 2 ). All compounds were stocked in 100% dimethylsulfoxide at 10 mM and diluted at graded concentrations (0.3 to 10 µM) with PBS running buffer (pH 7.4) containing 5% dimethylsulfoxide. The temperature of the instrument was set to 25 °C. Each compound (50 µl) was injected sequentially by flow rate 30 µl/min. NaOH (20 mM) was used to regenerate the active surface between cycles. 
Enzyme Inhibition Assays
Inhibition of each compound on PPIase activity of CypA was determined at 4 °C based on the published method with some modifications [14] . Suc-AAPF-pNA was dissolved in TFE containing 480mM of LiCl to a concentration of 3 mM. Then, α-chymotrypsin was dissolved in 1 mM HCl to a concentration of 42 mg/ml. Each test compound was diluted in 94 µl of assay buffer (50 mM HEPES, 100 mM NaCl; pH 8.0 at 0 °C), and then mixed with 2 µl of CypA solution (5 µM). After pre-equilibrating for 3 h on ice, 2 µl of α-chymotrypsin solution and 2 µl of peptide substrate were added to the assay mixture. Absorbance at the wavelength of 390 nm was recorded on a Jasco V-550 spectrophotometer (Jasco, Inc., Easton, MD) for 20 s. Three independent experiments were performed for each test compound.
RESULTS AND DISCUSSION
First Rule of the Protein-Ligand Interaction. FKBP12/FK506 separately (see Tables S1, S2 and S3 for more details about the frontier orbitals).
We define the energy difference between a protein and its ligand as
where E proteinLUMO is the average value of the active residues and E proteinHOMO is the highest value of HOMOs, ligandLUMO Especially, we have to point out that the results of CypA/CsA and FKBP12/FK506 are examples only. We calculated other several protein/ligand systems and obtained the same resulting relationship DE 1 < DE 2 as the above two systems without exception [15, 16] . Therefore, the DE 1 < DE 2 might be a generally correct relationship in proteinligand systems.
According to the frontier orbital theory, the perturbation energy of interaction between two molecules mainly comes from the interaction between HOMO and LUMO. If the energy of a protein is different from the energy of its ligand, the effect of the interaction produces an energy split. As a result, the smaller the energy difference between two orbitals, the stronger the interaction. Whether the interaction between two molecules can form a bond, it is related to the symmetry of the molecular orbital. We can, therefore, deduce the first rule on the protein-ligand interaction:
The protein-ligand interaction only occurs between the lowest unoccupied molecular orbitals (LUMOs) of a protein and the highest occupied molecular orbital (HOMO) of its ligand, not between the HOMOs of a protein and the LUMO of its ligand. Actually, it is the very characteristics of energy level structure of a protein that result in the first rule. The characteristics are that the LUMOs of a protein are always about 1.0 eV above the zero-energy-level, but its HOMOs are always far away below the zero-energy-level (about -10.0 eV). It is due to this kind of structure that the LUMOs of a protein are always near the HOMO of its ligand and the HOMOs of a protein are always far away from the LUMO of its ligand. That is why always there is the relationship DE 1 < DE 2 in the protein-ligand interaction. The first rule may be regarded as one of criteria of identifying a ligand. An interesting aside is that the wave function of a protein usually localizes on one or few residues (the occupancy item on Table 1 ).
Second Rule of the Protein-Ligand Interaction
According to the first rule, as a necessary condition, the active residues or active atoms of a protein must be located on the LUMOs of the protein, but conversely, not every residue on the LUMOs is certainly the active residue. When a ligand interacts with its target protein, it must enter into a pocket on the surface of the protein. For the same reason, only the pocket which has its forming atoms located on the LUMOs is the ligand binding site. Therefore, on the basis of the full electronic structure of a protein along with the pocket calculation, we can derive the second rule that only those residues or atoms located in both the LUMOs of a protein and a surface pocket of a protein are active residues or active atoms of the protein and the corresponding pocket is the ligand binding site. This is a necessary and sufficient condition for being the active residues or active atoms, as well as the ligand binding site. Now we can use this rule to check the active atoms of a protein. We selected CASTp method [17] to calculate pockets of protein. The CASTp is a geometry-based method of pocket detection, based on the alpha shape and discrete flow theory, and a related suite of programs. It can provide full descriptions of pockets on protein surface, including the atoms, residues, and volume of each pocket. For example, the CypA has a total of 19 pockets and the largest pocket is number 19. The FKBP12 has a total of 13 pockets. Table 2 and Table S4 show the pocket 19 of CypA and pocket 13 of FKBP12, respectively. Tables 3, 4 and Table S5 describe active atoms and their orbital coefficients of protein CypA, ligand CsA and FK506, and protein FKBP12, respectively.
We can see that none but the residues PHE60 and PHE113 are located not only on the LUMOs of CypA, but also in the pocket 19 (compare Table 1 and Table 2 ). All other residues on the LUMOs of CypA are not located in any other pocket. Therefore, we can say that the pocket 19 is the ligand binding site and the PHE113 and PHE60 are the active residues or that there are seven active atoms: PHE113: CG, CD1, CD2, CE1, CE2, and CZ (these six atoms form a quincunx in Fig. 4A ), and PHE60:CE2, as shown in Table 3 . Though the atoms PHE113: CB and PHE60: CZ are located on the LUMOs and in the pocket 19, their orbital coefficients are zero (Table 3) , thus they are not active atoms. Similarly, though the atoms PHE113: CA and PHE113: HB located on the LUMOs of CypA, they are not active atoms because they are not located in the pocket 19. It has been reported that CsA interacted with ARG55, PHE60, MET61, GLN63, GLY72, ALA101, ASN102, ALA103, GLN111, PHE113, TRP121, LEU122 and HIS126 of CypA [18] . The ligand binding pocket obtained by our method is number 19, which comprises ARG55, PHE60, MET61, GLN63, GLY72, THR73, GLY74, GLY75, LYS76, GLU81, LYS82, ALA101, ASN102, GLN111, PHE113, LEU122 and HIS126. They are in good agreement.
We can obtain the active residues of FKBP12 by the same way: TYR26, PHE36, PHE46, TRP59, PHE82 and PHE99 (compare Table 1 and Table S4 ), as well as the active atoms as shown in Table S5 . Therefore, the pocket 13 is the ligand binding site of FKBP12.
X-ray experiment reported that the binding pocket of FKBP12 comprised the residues TYR26, PHE46, PHE99, VAL55, ILE56 and TRP59 [19] . The active residues we worked out are TYR26, PHE36, PHE46, TRP59, TRY82 and PHE99. They are also in good agreement.
The residue MVA11 of the ligand CsA is on the HOMO of CsA. Therefore, MVA11 is the active residue of CsA. Four atoms of residue MVA11 on the HOMO with the absolute value of its atomic coefficient larger than 0.1 are considered to be the active atoms of the CsA: MVA11:N, MVA11:CA, MVA11:C and MVA11:O. And the active atoms of FK506 are: C2, C8, C9, C10, C11, N7, O3, O4 and O6 (Table 4 and Fig. 4B) . Fig. (4) shows the spatial configuration of the ligand binding pocket and the active atoms of CypA, CsA, FKBP12 and FK506. The active atoms of ligand are fitting so well with the active atoms of protein that indicates strong interactions between them (Fig. 4) . Especially, as NMR experiment pointed out [20] , the CsA changed its configuration so that its active residue MVA11 (the projecting part of the loop as shown in Fig. 4A) clearly trended toward the active part of CypA.
Peptide Inhibitor Ala-Gly-Pro
To verify the above two rules on the protein-ligand interaction, we designed a tripeptide Ala-Gly-Pro (AGP) to bind to CypA under guidance of the two rules (Please see the experimental section for more details about how and why AGP was selected). The calculation and biological experimental results showed perfect agreement with the two rules.
(1). Docking
The program Autodock [9] was employed to dock the AGP into the binding site of CypA. After docking, the complex system showed converged (Fig. 5) . The binding energy of docking was -7.25 Kcal/mol. And then energy minimization of 30ps was performed on the complex system. The structure of CypA/AGP complex remained stable and the AGP bound into the binding site perfectly as shown in Fig. (6A) . Additionally, the hydrophobic parts of the ligand AGP were embraced by the hydrophobic residues of CypA and so did the non-hydrophobic part. It demonstrates that interactions between AGP and CypA are reasonable from a chemical view.
(2). Active Resides and Active Atoms
We recalculated the electronic structure of AGP and CypA using the coordinates obtained after energy minimization. The active residues and active atoms of the CypA and AGP and the ligand binding site were obtained as shown in Fig. (6B) . The active residues of CypA are still the Phe60 and Phe113. There are two active residues (Pro, Gly) and seven active atoms of AGP, Pro: C, OT1, OT2, N, CA, HA and Gly: O. It has been reported through residue mutational experiments by Yoo et al. that residues Gly and Pro are the key determinants for CypA recognition [22] . Residues Pro and Gly are found to be active residues here and the active atoms localize mainly on the residue Pro, which is not only in excellent agreement with the previously findings. Furthermore, our work can identify the active atoms. The active atoms are located on right above the major active residue Phe113 of CypA (Fig. 6B) . The whole AGP fits into the binding pocket with perfect shape complementarity [23] as shown in Fig. (6A) , which is also consistent with the previous experimental findings that the CypA active site is complementary to sequences containing Table 4 and Table S5 ). The active atoms of FK506 (small colored balls) are embraced by the active atoms of FKBP12 (big orange balls). These pictures are generated by the program named VMD 1.8.6 [21] .
the dipeptide Gly-trans-Pro [8] . The HOMO of the ligand AGP is -2.26 eV, whereas that of the CsA is -4.75 eV. The LUMO energy of the CypA is 2.00 eV (Phe113). The binding energy of docking AGP to CypA is -7.25 Kcal/mol. Theoretically, these results are excellent.
(3). Binding Affinity Determination and Inhibition of PPIase Activity of CypA
The binding affinity of the designed peptides to CypA was measured by the Surface Plasmon Resonance (SPR) with Biacore 3000 instrument (BiacoreAB Corporation, Uppsala, Sweden) as previously described [24, 25] . AGP was detected to bind to CypA in a concentration dependent manner with K D value at 1.95×10 -6 M (Fig. 7A) , while CsA, as a positive control, showed a K D value at 6.42×10 -6 M (Fig. 7B) .
Since AGP could bind to CypA, we sequentially measured its inhibition on the enzyme activity of CypA. The standard spectrophotometric method was applied to determine the inhibitory activity of the compounds on PPIase. During the assay, the rate constants for the cis-trans conversion were evaluated by fitting the data to the integrated first-order rate equation through nonlinear leastsquare analysis as follows: Inhibitory rate (%) = [CypA (dAbs/time) -compounds (dAbs/time)] / [CypA (dAbs/time) -control (dAbs/time)]. The inhibition results are shown in Fig. (7) . As a positive control, CsA showed an inhibition of 59.95% against the PPIase activity of CypA at 1µM, while AGP an inhibition of 37.47% at 1µM.
Our designed peptide AGP has the same order of binding affinity and inhibition of PPIase activity as CsA. Besides, AGP has no impact on cell proliferation and cell cycle (data not shown). Therefore, peptide AGP may be new inhibitor for the CypA.
CONCLUSIONS
Assuming we now have a new target protein, we can work out its LUMOs and pockets only from its coordinate file, and we can immediately obtain its ligand binding site, active residues and active atoms. If the HOMO energy of a small molecule is far away from the LUMOs energy of the target protein, we are sure it can't be a ligand.
These two rules enable us to have a clearer understanding of the mechanism of protein-ligand interaction on the basis of full electronic structure of a protein. The real reason which created these rules is due to the characteristics of energy level structure of a protein. They could be an important criterion for identifying or designing a ligand for a target protein. The first rule tells us the necessary condition for being the active residues or active atoms that they must locate on the LUMOs of a protein, and permits us to identify a ligand by checking its HOMO energy level. We can use the energy eigenvalues and orbital coefficients of the wave function to calculate many other characteristics of a protein.
The second rule points out the necessary and sufficient condition for being the active residues/atoms and the ligand binding site. Therefore, it allows us to identify not only the ligand binding site, but also the active residues and active atoms of a protein. When detecting the active pocket, its volume and mouth-area can also help us identify or design a ligand.
As an application of our two rules, we predicted a tripeptide ligand AGP for the target receptor CypA. The peptide AGP was designed from scratch and is consistent with the previous experimental findings [8] indicating that the two rules we proposed can be criteria for guiding drug design. One may argue that the function of the designed peptide AGP is not surprising because this sequence ( 87 HAGPIA 92 ) has been reported to be essential for CypA recognition of the capsid domain of HIV-1 Gag polyprotein. However, another peptide Trp-Gly-Pro (WGP) was designed (after the current paper was finished) based on the rules [26] , providing additional support for two rules. As demonstrated by virtual screening experiment, 20 tripeptide X-Gly-Pro and 
